Todd Rambasek, MD
Allergy & Immunology · Sandusky, OHNPI 1093814220
Payments from drug & device makers
Across 373 payments — averaging $181.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$38K
- Amgen$11K
- Alk-abello, Inc$7K
- Regeneron$6K
- Genentech USA, Inc.$2K
- GSK$996
- plus $3K from 23 others
What the payments were for
- Consulting fees$1,7253%
- Speaking & faculty fees$42,50081%
- Travel & lodging$2160%
- Food & beverage$8,02915%
- Education$1660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 101 | $38,496 |
| Amgen(2 entities) | 51 | $10,975 |
| Alk-abello, Inc | 2 | $6,595 |
| Regeneron | 2 | $6,068 |
| Genentech USA, Inc. | 17 | $2,107 |
| GSK | 76 | $996 |
| CSL Behring | 15 | $400 |
| Regeneron Healthcare Solutions, Inc. | 19 | $354 |
| Optinose US, Inc. | 16 | $291 |
| Sanofi | 12 | $258 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $212 |
| Pfizer | 10 | $175 |
| Novartis | 6 | $165 |
| Teva Pharmaceuticals USA, Inc. | 9 | $145 |
| Sanofi-aventis U.S. LLC | 2 | $140 |
| Boehringer Ingelheim | 5 | $101 |
| Biocryst US Sales Co., LLC | 4 | $70 |
| Blueprint Medicines Corporation | 2 | $47 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Galderma Laboratories, L.p. | 2 | $30 |
| AbbVie | 1 | $25 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $21 |
| Cardinal Health 108 LLC | 1 | $20 |
| Shire North American Group Inc | 1 | $17 |
| Pharming Healthcare, Inc. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $14 |
| Organon | 2 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$67,831 in reported general payments places this provider in the 85th percentile of 128 allergy & immunology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 13 | $325,955 |
| Dupixent SyringeDupilumab | 53 | $202,616 |
| Dupixent PenDupilumab | 43 | $190,624 |
| XolairOmalizumab | 58 | $165,451 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $85,728 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $67,233 |
| Breo ElliptaFluticasone/Vilanterol | 91 | $62,273 |
| Spiriva RespimatTiotropium Bromide | 60 | $38,104 |
| DuleraMometasone/Formoterol | 28 | $15,193 |
| Arnuity ElliptaFluticasone Furoate | 46 | $14,836 |
| XhanceFluticasone Propionate | 19 | $14,681 |
| Ipratropium Bromide | 328 | $13,237 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $11,763 |
| Azelastine Hcl | 236 | $11,514 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $9,892 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $212 | $325,95513 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $996 | $172,066256 claims |
| CSL BehringHizentra | $400 | $67,23318 claims |
| Boehringer IngelheimSpiriva Respimat | $101 | $38,10460 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $38,496 | $18,64354 claims |
| Optinose US, Inc.Xhance | $291 | $14,68119 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $145 | $4,13111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 128 allergy & immunology providers in Ohio.
Other allergy & immunology in Sandusky
- Sridhar GuduriDublin$11.3M
- Donald McNeilColumbus$4.8M
- Jonathan BernsteinCincinnati$4.5M
- Syed RehmanToledo$3.6M
- David BernsteinCincinnati$2.7M
- Justin GreiweCincinnati$1M
- Sheharyar DurraniCincinnati$953K
- Juan AboniaCincinnati$515K
- Adam UpdegraffToledo$379K
- Gordon MyersCincinnati$346K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.